December Investor newsletter .... check it out on the media link in the Amplia website
Note from ... CEO and MD, Dr Chris Burns
ACCENT Clinical Trial Update
New Data Reveals Promise in Ovarian Cancer
Q&A with CMC Project Manager, Adrian Sulistio
There’s much to like.
My best bit .....
The data emerging from the Phase 1b study is encouraging ...
Not only has narmafotinib proven to be safe and well-tolerated, but early indicators also suggest promising efficacy.
Merry Christmas to all fellow investors let’s hope next year it’s going to be our year
One thing is for sure .... We have certainly laid the foundations for a promising year ahead
.
News: ATX Amplia Therapeutics Says Approval From Korean Regulator, page-11
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.5¢ |
Change
-0.005(3.33%) |
Mkt cap ! $41.21M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 15.5¢ | 14.5¢ | $47.81K | 319.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 161129 | 14.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| ATX (ASX) Chart |